<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Liu X</submitter><funding>National Key R&amp;amp;D Program of China</funding><funding>Zhejiang Research Center of Cardiovascular Diagnosis and Treatment Technology</funding><funding>Zhejiang Province Science and Technology Department Key R&amp;amp;D Program</funding><funding>The National Natural Science Foundation of China</funding><pagination>6502</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC9655232</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>11(21)</volume><pubmed_abstract>Evidence for transcatheter aortic valve implantation (TAVI) is scarce among patients with non-calcific aortic stenosis, and it is not known whether aortic valve calcification is associated with new cerebral ischemic lesions (CILs) that are detected by diffusion-weighted magnetic resonance imaging. So, our study enrolled 328 patients who underwent transfemoral TAVI using a self-expanding valve between December 2016 and June 2021 from the TORCH registry (NCT02803294). A total of 34 patients were finally confirmed as non-calcific AS and the remaining 294 patients were included in the calcific AS group. Incidence of new CILs (70.6% vs. 85.7%, &lt;i>p&lt;/i> = 0.022), number of lesions (2.0 vs. 3.0, &lt;i>p&lt;/i> = 0.010), and lesions volume (105.0 mm&lt;sup>3&lt;/sup> vs. 200.0 mm&lt;sup>3&lt;/sup>, &lt;i>p&lt;/i> = 0.047) was significantly lower in the non-calcific AS group. However, the maximum and average lesion volumes were comparable between two groups. Non-calcific AS was associated with lower risk for developing new CILs by univariate logistic regression analysis [Odds ratio (OR): 0.040, 95% confident interval (CI): 0.18-0.90, &lt;i>p&lt;/i> = 0.026] and multivariate analysis (OR: 0.031, 95% CI: 0.13-0.76, &lt;i>p&lt;/i> = 0.010). In summary, non-calcific AS patients had a lower risk of developing new cerebral ischemic infarction after TAVI compared to calcific AS patients. However, new ischemic lesions were still found in over 70% of patients.</pubmed_abstract><journal>Journal of clinical medicine</journal><pubmed_title>Cerebral Ischemic Lesions after Transcatheter Aortic Valve Implantation in Patients with Non-Calcific Aortic Stenosis.</pubmed_title><pmcid>PMC9655232</pmcid><funding_grant_id>81770252</funding_grant_id><funding_grant_id>JBZX-202001</funding_grant_id><funding_grant_id>81870292</funding_grant_id><funding_grant_id>2022C03063</funding_grant_id><funding_grant_id>81570233</funding_grant_id><funding_grant_id>2019YFA0110400</funding_grant_id><funding_grant_id>2018C03084</funding_grant_id><funding_grant_id>2021C03097</funding_grant_id><pubmed_authors>Chen J</pubmed_authors><pubmed_authors>Guo Y</pubmed_authors><pubmed_authors>Liu Q</pubmed_authors><pubmed_authors>Zhu G</pubmed_authors><pubmed_authors>Wei Y</pubmed_authors><pubmed_authors>Wang J</pubmed_authors><pubmed_authors>Yidilisi A</pubmed_authors><pubmed_authors>Liu X</pubmed_authors><pubmed_authors>He Y</pubmed_authors><pubmed_authors>Fan J</pubmed_authors><pubmed_authors>Qi X</pubmed_authors><pubmed_authors>Zhou D</pubmed_authors><pubmed_authors>Zhu Q</pubmed_authors><pubmed_authors>Dai H</pubmed_authors></additional><is_claimable>false</is_claimable><name>Cerebral Ischemic Lesions after Transcatheter Aortic Valve Implantation in Patients with Non-Calcific Aortic Stenosis.</name><description>Evidence for transcatheter aortic valve implantation (TAVI) is scarce among patients with non-calcific aortic stenosis, and it is not known whether aortic valve calcification is associated with new cerebral ischemic lesions (CILs) that are detected by diffusion-weighted magnetic resonance imaging. So, our study enrolled 328 patients who underwent transfemoral TAVI using a self-expanding valve between December 2016 and June 2021 from the TORCH registry (NCT02803294). A total of 34 patients were finally confirmed as non-calcific AS and the remaining 294 patients were included in the calcific AS group. Incidence of new CILs (70.6% vs. 85.7%, &lt;i>p&lt;/i> = 0.022), number of lesions (2.0 vs. 3.0, &lt;i>p&lt;/i> = 0.010), and lesions volume (105.0 mm&lt;sup>3&lt;/sup> vs. 200.0 mm&lt;sup>3&lt;/sup>, &lt;i>p&lt;/i> = 0.047) was significantly lower in the non-calcific AS group. However, the maximum and average lesion volumes were comparable between two groups. Non-calcific AS was associated with lower risk for developing new CILs by univariate logistic regression analysis [Odds ratio (OR): 0.040, 95% confident interval (CI): 0.18-0.90, &lt;i>p&lt;/i> = 0.026] and multivariate analysis (OR: 0.031, 95% CI: 0.13-0.76, &lt;i>p&lt;/i> = 0.010). In summary, non-calcific AS patients had a lower risk of developing new cerebral ischemic infarction after TAVI compared to calcific AS patients. However, new ischemic lesions were still found in over 70% of patients.</description><dates><release>2022-01-01T00:00:00Z</release><publication>2022 Nov</publication><modification>2025-04-25T23:27:04.965Z</modification><creation>2025-04-06T09:21:16.19Z</creation></dates><accession>S-EPMC9655232</accession><cross_references><pubmed>36362730</pubmed><doi>10.3390/jcm11216502</doi></cross_references></HashMap>